HPV genotypes and epidemiology in women cervical cancer in Senegal.

**CURRENT STATUS:** UNDER REVIEW
Amadou Alpha Sall
Institut Pasteur de Dakar

Ahmadou DEM
Universite Cheikh Anta Diop Faculte de Medecine de Pharmacie et d'Odontologie

DOI:
10.21203/rs.2.15323/v2

SUBJECT AREAS
Infectious Diseases
Abstract

Background In sub-Saharan Africa, cervical cancer is increasing steadily, with more than 75,000 new cases and nearly 50,000 deaths a year (Mboumba et al., 2017). In Senegal, pathologies such as cervical cancer are at the top of the causes of death and Human papillomavirus (HPV) is the aetiological agent (Steenbergen et al., 2005). Methods The aim of the study is to analyze the distribution of HPV among Senegalese women with cervical cancer. Main objectives of this study are to identify the HPV types associated or “co-associated” with cervical oncogenesis in Senegal. The correlations with risk factors of cervix carcinogenesis, with risk factors, were analyze too. Cervical biopsies were performed on women hospitalized at Aristide Hospital Le Dantec-Julio Curie Institute. Three methods has been used to detect HPV genotypes - SANGER sequencing genotyping (Applied BioSystems), PCR real-time approach technique (HPV 16 & 18 RealTime PCR kit) (www.bioneer.co.kr) and the genotyping approach from Chippron (HPV kit 3.5 LCDArray) (info@chipron.com). Results In this study, patients had multiple infections (co-infections) at all, and the majority of coinfections was High-risk types (HR-HPV types). The most common type of HPV in our study were 16 (systematically detected in more than half of our patients), 18 (44%), 45 (33%), 33 (31%), 59 (28%), 35 (12%), 31 (11%), 58 (8%), 39 and 73 (4%), 44, 54 and 68 (3%) and the rest less than 1%. Among co-infections detected in different regions of Senegal among women with cervical cancer, we found that HPV types 16 and 18 had the highest prevalence. In the Dakar region, which had the highest number of cases, a prevalence of 17.89% of HR-HPV co-infections was noted. Conclusion Polygamy represents a cofactor in the occurrence of cervical cancer in Senegalese women. No association between HPV-High Risk co-infections and cancer stages.

Background

Cervical cancer is the fourth commonest cancer affecting female population in the world, and the seventh most common cancer in the general population worldwide (Bray et al, 2018). The disease is also the fourth leading cause of cancer death among women with 311,000 associated deaths in 2018. The highest regional incidence and mortality rates are seen in Africa, especially in Eastern (Malawi, with the highest mortality rate ; and Zimbabwe) and Western Africa (Guinea, Burkina Faso, and Mali).
Globally, it was previously admitted that low- and middle-income countries account for almost 90% of the burden of cervical cancer (WHO, 2014) due to insufficient awareness, lack of effective screening programs, and late clinical presentation. In addition, reports of trends in cervical cancer mortality in these countries have been limited by poor data quality and inaccurate estimates of population (Bailey et al, 2016). Additionally, in most of these countries, especially in sub-Saharan Africa, there is no cancer registry. Human papillomavirus (HPV) is a causative agent of cervical cancer that has been detected in 99.7% of cervical squamous cell carcinoma and in 94-100% of cervical adenocarcinoma (Steenbergen et al, 2005). HPV is transmitted through sexual intercourse or skin-to-skin genital contact (Hernandez et al, 2008), and persistent infection with high-risk HPV (HR-HPV) is the major cause of cervical intraepithelial neoplasia and invasive cervical cancer (Munoz et al, 1992 ; Schiffman et al, 1993 ; Walboomers et al, 1999). In general, most infections resolve on their own, as the immune response controls infection and prevents progression to precancerous lesions (Rodriguez et al, 2008).

Papillomaviruses are circular, nonenveloped double-stranded DNA viruses with a genome length of 8 kb. More than 200 HPV genotypes have been reported and grouped into cutaneous and mucosal types according to their site of infection, and then subdivided into high risk (HR) and low risk (LR) types, depending on their association with a particular infection. Malignant disease (IARC, 2011). Based on epidemiological studies conducted mainly in developed countries, HPV16 and HPV18 are the two most common types of HR in cervical cancer, accounting for about 70% of all cases worldwide (Ramakrishnan et al, 2015). Sensitivity to risk factors for cervical cancer may facilitate public participation in screening campaigns, including young age at first intercourse, (Jimenez et al., 1999, Louie et al., 2009), multiple sexual partners, (Brinton et al., 1989) multiparity, (Castellsague et al., 2003, Brinton et al., 1989) human papillomavirus infections, (Walboomers et al., 1999, Bosch et al. Al, 2007) the first term pregnancy (Appleby et al 2006). Similarly, early research for help may be encouraged if women in middle-income countries are more aware of the symptoms of cervical cancer – menopausal vaginal bleeding, postcoital vaginal bleeding, superficial vaginal discharge, and lower abdominal pain. (Petignat et al., 2007, Lea et al., 2012)

In Senegal, a West African country, a high-incidence and cervical cancer mortality area (Bray et al,
data on cervical cancer and related genotypes are scarce. While genotype HPV-16 is the most common cervical cancer genotype in the world, the prevalence of other genotypes varies geographically (Crow et al., 2012). These data are highly variable and incomplete in Africa. Thus, the prevalence and distribution of HPV genotypes in Africa among women with invasive cervical cancer is necessary. Until now, two vaccines were available: the «old» Gardasil®, which contains two oncogenic HPV genotypes (HPV 16 and 18) and two other genotypes of HPV responsible for condyloma acuminata, and Cervarix®, which contains HPV 16 and 18. Both vaccines provide 70% protection against cervical cancer. To cover a broader spectrum of oncogenic HPV, a new Gardasil-9® vaccine was developed in 2016 with additional genotypes included (HPV 31, 33, 45, 52 and 58) and an expected protection against 90% of HPV-induced cervical cancers.

In Senegal, a study of a general population of women aged 18 and over in many regions (Mbaye et al., 2014) showed that the risk of HPV infection was estimated at 22.8%. Mbaye et al. (2014) also demonstrated that the HPV 31.52 and 53 genotypes were the most prevalent in the general population of women in Senegal. Here, we set ourselves the goal of studying the distribution of HPV genotypes among Senegalese women with confirmed cervical cancer in order to see the rate of regression of this cancer with the introduction of the Gardasil vaccine. -9®.

Methods

//Study population //

This was a cross-sectional study on cervical cancer surveillance conducted between 2013 and 2017. HPV genotype screening was performed on 120 samples of cancerous tissue. These tissues were biopsies made at the Joliot Curie Institute of the Aristide Le Dantec Hospital in Dakar on women with cervical cancer. These patients came from different parts of Senegal and had a pathology of the cervix. All mentally and physically competent women aged 18 or older diagnosed with invasive cervical cancer (ICC) are included in the study after receiving the necessary counseling and consent to participate in the study. All patients with HIV infection were excluded. Patients were free to refuse inclusion (although all the patients we met agreed to participate in the study). For each consenting
woman, data relating to age, sex, place of birth, place of residence, year of tumor diagnosis, tumor site, histology, clinic, received and the evolution of the disease, are collected on a dedicated form.

//DNA extraction, HPV L1 gene and PCR-Sanger Sequencing //
For each sample DNA was extracted from tissue using the Qiagen DNeasy® Blood & Tissue Kit (QIAGEN, Valencia, CA, USA) according to the manufacturer’s recommendations. A 450 bp long fragment of the HPV L1 gene was targeted using the MY09/MY11 consensus primers previously described (Bauer et al, 1991). The PCR reactions were performed using a Gotaq ® Green Master Mix (Promega, Germany) in a total volume of 25 μl containing 5 μl of genomic DNA (5 ng/μl), 1.5 μl of each primer (10 μM), 12.5 μl of Master Mix, and 4.5 μl H2O DNase free. Cycling conditions were as follow: initial denaturation step at 95 °C for 5 min, 35 cycles including each 95 °C for 30 s, 62 °C for 45 s, and 72 °C for 1 min, and a final extension at 72 °C for 10 min. For positive samples, amplicons were purified using BioGel P100 gels (Bio-Rad) and nucleic acid quantified for Sanger sequencing. The corresponding genotypes were determined using Blast software and compared with the set of genomic sequences available in the GenBank database.

//HPV Genotyping Technique using the Chippron Approach (HPV 3.5 LCD-Array Kit) (www.chipron.com) //
It consists of a specific identification of 32 HPV genotypes, with a single hybridization on a combination of independent robust PCR amplifications in a matrix field. Combined PCR allows parallel and robust detection of HPV types at 5 target copies per reaction for HPV 16, 18, and 31 types and at 50 target copies for all others. Both, primer mixtures are directed against highly conserved motifs in the genome. Primer mixture ‘A’ generate fragments of about 450 bp in length; while mixture ‘B’ generate amplicons around 165 bp long (depends on the type of HPV). Generated PCR product of small amplicons were biotinylated, labeled and hybridized to species-specific capture probes immobilized on the surface of the LCD chip. A cascade of enzyme substrates allows short and highly stringent visualization of the bound amplicon and each LCD chip contains eight identical microarrays separated into individually addressable small reaction chambers.

//Real-time PCR-genotyping using the Bionner approach //
The BIONEER team has designed a kit to detect HPV16 and HPV18 genotypes by real-time PCR approach (rRT-PCR). Bionner tests are performed in a closed system in three steps: DNA extraction, RT-PCR steps and Data analysis.

//Statistical analysis //

Statistical analysis was performed to evaluate the global distribution and the association between Cervix Cancer clinical status and HPV genotypes via R software. HPV Genotypes estimate were obtain using the R logistic software (R Development Core Team (2010)). Differences in HPV genotypes frequencies among stages of the disease (Figo classification groups), and other factors (age, marital status, gesture, parity, number of partners and profession), were examined using the chi-squared test, and differences were considered statistically significant for p-values <0.05. Nominal p values were corrected under listed cofounders’ factors such as age, marital status, gesture, parity, number of sexual partners and profession. For age, the women were classified into 3 age groups (<45, 45-55, >55) and 2 groups for the oncogene HPV genotypes (<or=2 and >2).

Results

//Demographic and clinical characteristics //

Between 2013 and 2017, a total of 120 women from different regions of Senegal diagnosed with cervical cancer were included in the study. Fresh cervical biopsies were taken from each patient and screened for HPV. Regarding their kinetic aspects, 85 of our patients or 70.83% were in stage II (figo class), 32 or 26.66% in stage III and 3 (2.5%) in stage IV. The age of the patients varied from 27 to 85 years with an average age at diagnosis of 50.62 years and a median age of 50 years. Regarding age groups, 35 patients (29.2%) were under 45 years of age, 51 (42.5%) between 45 and 55 years of age and 34 (28.33%) of patients were over 55 years.

//HPV types prevalence //

Several types of HPV were detected in this study. Gathering the results obtained with the 3 technical approaches, a total of 23 HPV genotypes were detected in our patients. The most common genotypes in our population were HPV16 systematically detected in more than half of our patients, 18 (44%), 45 (33%), 33 (31%), 59 (28%), 35 (12%), 31 (11%), 58 (8%), 39 and 73 (4%), 44, 54 and 68 (3%) and the
rest less than 1%.

// HPV 16 and 18 distribution//

The cartography of genotypes by area, showed that the genotypes 16 and 18 co-dominated in Dakar, Thiès, Diourbel, Saint-Louis, Fatick, Kaolack, Tambacounda, Kedougou and Ziguinchor areas, while in Kolda genotype 16 was the most prevalent. In the kaffrine area we have only 2 genotypes on the 39 and 59

//HPV types coinfections and cofactors. //

We found 29 unique cases of single genotype infection in our patients. In fact, co-infections with at least 2 genotypes accounted for 33.3% (40/120) of the cases. In 49 samples (40.83%), more than two viruses were detected. Co-infections with 3 dominated HPV genotypes (26 patients) followed by 4 genotypes (15 patients), 5 genotypes (6 patients) and 6 genotypes (2 patients).

We noted that co-infections with several HR-HPVs were predominant in polygamous patients (p value of 0.02) compared to patients with monogamous status (OR of 0.30). For the gestity criterion, coinfections with multiple genotypes (up to 6 genotypes) were more frequent in patients who had 6 pregnancies or more (OR = 1.60). We also noted that co-infections with multiple genotypes were significantly associated to patients older than 45 years (OR> 1). The association analysis between HRHPV coinfections and age showed that HR-HPV co-infections were more prevalent among "young" patients (<45 years old) with 35 cases and those aged between 45 and 55 years (41 cases). In both groups, co-infection with more than 2 HR-HPV genotypes dominated (79 cases vs 41 with 2 or less).

Discussion

Cervical cancer (CC) is a scourge that imposes a therapeutic emergency. This cancer is increasing steadily in sub-Saharan Africa, with more than 75,000 new cases and nearly 50,000 deaths a year (Steenbergen et al., 2005)(Mbouamba et al., 2017). According to the World Health Organization, CC is the fourth most common affecting female population worldwide, and will kill more than 443,000 people worldwide by 2030, nearly 90% of them in sub-Saharan Africa. This high incidence may be justified by the lack of adequate structure for diagnosis, screening and treatment (Castellsague et al., 2007). In Senegal, CC is the first most common cancer of women (ICO/IARC HPV Information Center,
2019), and here we reported a pilot study exclusively dedicated to the distribution of HPV genotypes among Senegalese women with cervical cancerous lesions.

As expected, all cervical specimens collected in women with histologically confirmed ICC were HPV-positive with at least one genotype detected. The most commonly detected HPV types in women with single or multiple HPV infections were HPV16 (systematically detected in more than half of our patients), 18 (44%), 45 (33%), 33 (31%), 59 (28%), 35 (12%), 31 (11%), 58 (8%), 39 and 73 (4%), 44, 54 and 68 (3%) and the rest less than 1%. The high prevalence of HPV16 and HPV18 reported in our study was expected, since these types are the two most common HPV types across the world (de Sanjose et al., 2010; Li et al., 2011; de Oliveira et al., 2013; Deny et al., 2014; Lagheden et al., 2018; Liao et al., 2018). However in some studies (Mejia et al., 2015; Wang et al., 2018; Schisler et al., 2018; Long et al., 2018), other genotypes (HPV45, 58, 52) had been reported as the second commonest. This result agrees with that of Missaoui et al., 2010 had found that HPV16 is the most frequent virus among invasive squamous cell carcinomas (47.6%, p = 0.001) and adenocarcinomas (80%, p <0.001) in Africa from the north (Tunisia). On the other hand, in Central Africa more precisely in Cameroon, the prevalence of the HPV 16 and, HPV 18 genotypes represented 30.8% (Tebeu et al., 2018).

//Infections and cofactors //

we also noted that most women were infected with at least one high-risk HPV (70%). This high co-detection rate is especially due to the high sensitivity of the Chippron real-time PCR test which targeted a wide range of genotypes but also of the fact that the almost totality of our patients were under polygamous regime. We know that being sexually active and having many sexual partners increases the risk of the most virulent papillomavirus infections. In Senegal, patients do not accept to tell you how many sexual partners they have, but we do have polygamy, the most frequent marital situation and that the majority of these patients were under this regime hence our assertion that polygamy is a risk factor. Indeed polygamy can involve the diversity of the noted genotypes as well as the high number of coinfection. Overall, it was noted that the proportion of HPV multiple infections increased in the last years from 4% to 15% (Li et al., 2011), reflecting the use of new tests more prone to detect multiple infections in recent studies.
Multiple HPV infections could, in part, explain the special aggressivity and the rapid progression of the cervical cancer disease noted in the Senegalese women as it was reported as an independent predictor of poorer survival another study (Genta et al, 2017). However the mechanism how multiple HPV infections affects patients survival is not fully understood. We also noted that co-infections with more than 2 HR-HPV types were especially prevalent in patients between 45 to 55 years age, probably due to viral persistence or reactivation of latent HPV (Simon and Poppe 2008; Dufit et al., 1991).

With regard to marital status, multiple HR-HPV co-infections were significantly more prevalent among polygamist. We also noted that women with more than six pregnancies were prone to multiple coinfections. Both results are in line with previous results which clearly indicated that multiple pregnancies and the high number of sexual partners increase the risk of HPV infection and persistence (IARC, 2016).

// Link with Vaccines //

Based on the new Gardasil-9® vaccine which operates against 9 HPV genotypes (6, 11, 16, 18, 31, 33, 45, 52 and 58), only 5 ICC cases were exclusively associated with non-vaccine types. So regarding the results obtained in the present study, the use of this nonavalent vaccine might provide an effective prevention outcomes for cervical cancer in Senegalese adolescent girls or young women, with the expectation to prevent up to 95% of ICC. However, further studies including more patients are needed for a better asessment of the real impact of this nonavalent vaccine.

Regarding the vaccination perspectives, the relatively high prevalence of the non vaccine types HPV59 (18.33%) and HPV35 (11.66%) could be a public health issue in Senegal, but once again additional studies are needed to confirm these findings.

However some limitations can be pointed out of this study. Firstly, the modest sample size included in this study. Indeed, unfortunately only few cases were sampled and tested, and the HPV genotypes prevalence reported here should be considered as trends which need confirmation through additional more exhaustive studies. Secondly, the high prevalence of multiple infections, sometimes with more than 3 genotypes, complicates the establishment of the carcinogenic value of some HPV types or
group of HPV types. Genotypes viral load determination by quantitative methods would probably help to have an idea about the more carcinogenic types or combinations ‘types’ associated with (ICC) in Senegal.

Conclusion

In conclusion, the overall frequency of HPV types detected in cervical cancerous lesions was high for HPV16 and HPV18 in Senegal. Multiple infections were also very common. Globally, our findings can be beneficial to health policy decision-makers and shows that current HPV vaccines, especially the current 9-valent one, could have great impact to reduce the burden of cervical cancer in Senegal. However a special attention should be drawn on some non vaccine types (HPV 59 and 35 especially) which could emerge as leading causes of cervical cancer in a context of HPV vaccination in Senegal.

Abbreviations

HPV : Human Papillomavirus

Declaration

*Authors’ contributions and details.

(NK), (DCT), (DG), (DN), (TC), (LC), (NM\(^1\)), (NM\(^2\)), (DA), (KS), (DA), (SA), (DA).

NK, DCT, DN and DG concepted the study, the methodology, conducted the study, drafted the manuscript and approved the final version.

*TC and LC conducted the data analysis and approved the final version.

*CD and KN conducted the methodology, to performing molecular biology, and approved the final version.

*NM\(^1\) and DA contributed to the recruitment and managment of the Cervix Cancer Cases and approved the final version.

*DA, DN and DA coordinated this study, revised the manuscript.

*All authors read and approved the final manuscript.

Availability of data and materials : the data of this study are disponibles

Consent to participate : The participants gave their consent in a form and signed

* Corresponding Author: Khadidiatou NIANE

Email: dija.bec@gmail.com kniane@pasteur.sn
**Telephone:** +221777509207

*Ethical approbation of the study*

Our protocol has been reviewed according to the rules issued by the National Committee for Ethics for Health Research (CNERS) of Senegal and in accordance with the procedures established by the University Cheikh Anta Diop Dakar (UCAD) for the ethical approval of any research involving human participants. Based on the information provided in the protocol, UCAD’s Committee on Research Ethics (CER) considers that the research proposed, respects the appropriate ethical standards and, as a result, approves its execution under “Protocole 0224/2016/CER/UCAD”.

*Consent to publish* : Not Applicable

*Acknowledgements*

The authors are grateful to all the patients and medical staff who have generously collaborated in this study. Authors thanks to the staff of the Cancerology Aristide LeDantec Hospital (Dakar, Senegal) assistance in inclusion/recruitment. The Senegal Ministry of Education and Research and Institute Pasteur of Dakar (Senegal) supported the PhD Candidate NK.

*Funding*

This study was supported by grants from :

- Senegal Ministry of Research : Accompanied us in the recruitment of patients, the acquisition of a laptop and the travel costs for recruitment.
- Institut Pasteur of Dakar : Accompanied us with reagents for lab work and will cover publication costs

*Competing interests*

The authors declare that they have no competing interests.

References

1. Saadi, M.A. Tazi, A. Er-raki, N. Benjaafar, N. Bennani Mechida, M. Mrabet, R. Razine. Analyse de survie au cancer du col de l’utérus à Rabat (Maroc) de 2005 à 2008. Doi : 10.1016/j.respe.2015.03.107. © 2015 Publié par Elsevier Masson SAS.
2. Appleby P, Beral V, de Berrington A et al. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16 563 women with cervical carcinoma and 33 542 women without cervical carcinoma from 25 epidemiological studies. International Journal of Cancer, 2006; 119: 1108-1124.

3. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens. Part B: biological agents. Lancet Oncol 2009; 10(4):321.

4. Behtash N, Mehrdad N. Cervical cancer: screening and prevention. Asian Pac J Cancer Prev 2006;7(4):683.

5. Brinton LA, Reeves WC, Brenes MM et al. The male factor in the etiology of cervical cancer among sexually monogamous women. International Journal of Cancer, 1989; 44: 199-203.

6. Brinton LA, Reeves WC, Brenes MM et al. Parity as a risk factor for cervical cancer.

7. Bosch FX, de Sanjose S. The epidemiology of human papillomavirus infection and cervical cancer. Disease Markers, 2007; 23: 213-227.

8. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2018, 68, 394-424.

9. Brenda Y. Hernandez, Lynne R. Wilkens, Xuemei Zhu, Pamela Thompson, Katharine McDuffie, Yurii B. Shvetsov, Lori E. Kamemoto, Jeffrey Killeen, Lily Ning, and Marc T. Goodman. Transmission of Human Papillomavirus in Heterosexual Couples. Emerg Infect Dis. 2008 Jun; 14(6): 888-894. doi: 10.3201/eid1406.070616.2.

10. Castellsague X, Munoz N. Chapter 3: cofactors in human papillomavirus carcinogenesis—role of parity, oral contraceptives, and tobacco smoking. Journal of the National Cancer Institute, 2003; 31: 20-28.

11. De Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype
14. attribution in invasive cervical cancer: a retrospective crosssectional worldwide study. Lancet Oncol 2010;11: 1048–56.

12. Elfgren K, Jacobs M, Walboomers JM, Meijer CJ, Dillner J. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynecol 2002;100(5 Pt 1):965.

13. GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2018, 68, 394–424.

14. Howard H.Bailey, Linus T. Chuang, Nefertiti C., Cathy Eng, Lewis E. Foxhall, Janette K. Merrill, Dana S. Wollins, Charles D. Blanke. American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer. J Clin Oncol 34. © 2016 by American Society of Clinical Oncology. doi/10.1200/JCO.2016.67.

15. Huraux, H.Agut, J.Nicolas, H.Peigue. La Feuille N. 2003. Traité de virologie médicale. Paris : ESTEM (Agence Engl J Med 2006 ; 354 : 1343-51).

16. Jimenez P, Thomas DB. Has the use of pap smears reduced the risk of invasive cervical cancer in Guadalajara, Mexico? International Journal of Cancer, 1999; 82: 804–809.

17. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927–35.

18. Louie KS, de Sanjose S, Diaz M et al. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. British Journal of Cancer, 2009; 100: 1191- 1197.

19. Lea JS, Lin KY. Cervical cancer. Obstetrics and Gynecology Clinics of North America, 2012; 39: 233-253.

20. Mboumba BouassaRS, Prazuck T,LethuT, Meye JF, Be ’lec L. Cancer du col de l’utérus
en Afrique subsaharienne: une maladie associée aux papillomavirus humains oncogenes, emergente et évitable. Med Sante Trop 2017; 27: 16-22. doi: 10.1684/mst.2017.0648.

21. Mougin C., Bernard B., Lab M., Biology of papillomavirus infections. I. General characteristics, Ann. Biol. Clin. (Paris) 55(6) (1997)555-563.

22. Muñoz N., Castellsagué X., de Gonzalez AB., & Gissmann L. (2006). Chapter 1: HPV in the etiology of human cancer. Vaccine, 24 Suppl 3: S3/1-10.

23. Munoz N, Bosch FX, de Sanjose S, et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case–control study in Colombia and Spain. Int J Cancer. 1992;52:743-9.

24. Petignat P, Roy M. Diagnosis and management of cervical cancer. BMJ (Clinical research ed.), 2007; 335: 765-768.

25. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents, vol. VIII. Lyon: IARC Scientific Publications No. 155 IARC; 2002.

26. Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, Solomon D, Burk R. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008;100:513-7.

27. Ramakrishnan S, Partricia S, Mathan G. Overview of high-risk HPV’s 16 and 18 infected cervical cancer: pathogenesis to prevention. Biomed Pharmacother. 2015;70:103-10.

28. R Development Core Team (2010). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL, http://www.Rproject.org.

29. Renske DM Steenbergen, Jillian de Wilde, Saskia M. Wilting, Antoinette ATP Brink, Peter JF Snijders and Chris JLM Meijer. HPV-mediated transformation of the anogenital
tract. Journal of Clinical Virology 2005, 32: 25-33. doi: 10.1016/j.jcv.2004.11.019.

30. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993; 85: 958-64.

31. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-9.

32. World Health Organization (WHO). World Cancer Report 2014. Available from: http://publichealthwell.ie/node/725845.

33. http://gco.iarc.fr/today/data/factsheets/populations/686-senegal-fact-sheets.pdf [consulté le 02 février 2019].

34. http://bioneer.co.kr. [consulté le 12 mars 2018].

35. http://info@chipron.com. [consulté le 09 juin 2018].

Tables

Table I A: Demographic and clinical characteristics (Age and Stade-classe figo)

| Age     | Number of patients | Stade II | Stade III | Stade I |
|---------|--------------------|----------|-----------|---------|
| <45     | 35 (29.16%)        | 85 (70.83%) | 3 (2.5%) |
| 45-55   | 51 (42.5%)         | 32 (26.66%) |          |
| >55     | 34 (28.33%)        |          |          |

Table IB: Demographic and clinical characteristics (year of diagnosis, place of residence, Gestity and first sexual rapport)

West: Dakar , Thies, Diourbel ; Center: Kaolack, Kaffrine, fatick.Louga ; North: Saint-Louis ; South: Kolda, Kédougou, Ziguichor

Table II: Number of percentage of genotypes

Table III: Correlation between risk factors and HR-HPV coinfects. HPV, human papillomavirus; HR,
| Number of patients | year of diagnosis | 2013-2015 | 2016-2017 | West | Center | North | South | <5   | 5-10  | >10  |
|-------------------|------------------|-----------|-----------|------|--------|-------|-------|------|-------|------|
|                   |                  |           |           |      |        |       |       |      |       |      |
|                   |                  | 48 (40%)  | 72 (60%)  | 58 (48.33%) | 25 (20.83%) | 11 (9.16%) | 26 (21.66%) | 24 (20%) | 84 (70%) | 12 (10%) |
| Percentage        | <10%             |           | 10-20%    |       |       |       |       |      |       |      |
| Genotypes         | 58-39-73-44-54   | 68-42-67-72-82 | 29-51-52-66-81 | 89-56 | 31-35 |       |       |      |       |      |
|                   |                  |           |           |      |        |       |       |      |       |      |
| high-risk; Gest, Gestity; Pol, Polygamy; Gest: Gestity ; Mono, Monogamy; P: p-value; OR: Odds Ratio. |
|        | ≤2 HR-HPV | >2 HR-HPV | OR (univariable) | OR (multivariable) |
|--------|-----------|-----------|------------------|-------------------|
| Sit    | poly      | 32 (78.0) | 71 (92.2)        | -                 | -                 |
|        | mono      | 9 (22.0)  | 6 (7.8)          | 0.30 (0.09-0.90, p=0.034) | 0.30 (0.09-0.93, p=0.039) |
| Gest   | <=6       | 24 (58.5) | 37 (46.8)        | -                 | -                 |
|        | >6        | 17 (41.5) | 42 (53.2)        | 1.60 (0.75-3.47, p=0.225) | 0.63 (0.07-4.57, p=0.648) |
| Age    | <45       | 15 (36.6) | 25 (31.6)        | -                 | -                 |
|        | >55       | 12 (29.3) | 22 (27.8)        | 1.10 (0.42-2.88, p=0.844) | 0.84 (0.29-2.41, p=0.751) |
|        | 45-55     | 14 (34.1) | 32 (40.5)        | 1.37 (0.56-3.39, p=0.490) | 0.94 (0.35-2.53, p=0.909) |
| Stade  | II        | 12 (29.3) | 28 (35.4)        | -                 | -                 |
|        | III_&_IV  | 29 (70.7) | 51 (64.6)        | 0.75 (0.33-1.68, p=0.497) | 0.77 (0.32-1.78, p=0.547) |

Figures
Figure 1

The cartography of HPV genotypes (HPV 16 and 18 co-dominated in Dakar, Thiès, Diourbel, Saint-Louis, Fatick, Kaolack, Tambacounda, Kedougou and Ziguinchor areas, while in Kolda genotype 16 was the most prevalent. In the kaffrine area we have only 2 genotypes on the 39 and 59.
The cartography of HPV genotypes (HPV 16 and 18 co-dominated in Dakar, Thiès, Diourbel, Saint-Louis, Fatick, Kaolack, Tambacounda, Kedougou and Ziguinchor areas, while in Kolda genotype 16 was the most prevalent. In the kaffrine area we have only 2 genotypes on the 39 and 59.
The cartography of HPV genotypes (HPV 16 and 18 co-dominated in Dakar, Thiès, Diourbel, Saint-Louis, Fatick, Kaolack, Tambacounda, Kedougou and Ziguinchor areas, while in Kolda genotype 16 was the most prevalent. In the kaffrine area we have only 2 genotypes on the 39 and 59.